CA
NZ
UK
AU
IND
US
…
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Income before tax | -196.45M | -88.66M |
| Net income | -191.94M | -88.66M |
| Selling general administrative | 48.75M | 12.36M |
| Reconciled depreciation | 5.85M | 0.35M |
| Ebit | -201.84M | - |
| Ebitda | -195.99M | - |
| Depreciation and amortization | 5.85M | - |
| Operating income | -201.84M | -96.66M |
| Other operating expenses | 201.84M | - |
| Tax provision | -4.51M | 0.00M |
| Interest income | 6.85M | 1.29M |
| Net interest income | 6.85M | 1.29M |
| Income tax expense | -4.51M | - |
| Total revenue | 0.00M | 0.00M |
| Total operating expenses | 201.84M | 96.66M |
| Total other income expense net | 5.38M | 6.71M |
| Net income from continuing ops | -191.94M | -88.66M |
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Total assets | 390.94M | 63.53M |
| Intangible assets | 23.23M | - |
| Other current assets | 9.87M | 0.92M |
| Total liab | 641.28M | 146.72M |
| Total stockholder equity | -250.34M | -83.19M |
| Other current liab | 26.40M | 0.26M |
| Capital stock | 0.00M | 0.00M |
| Retained earnings | -281.09M | -89.15M |
| Cash | 108.99M | 49.40M |
| Total current liabilities | 37.54M | 8.29M |
| Net debt | -95.16M | - |
| Short term debt | 3.14M | - |
| Short long term debt total | 13.83M | - |
| Other stockholder equity | 30.69M | - |
| Total current assets | 345.35M | 50.32M |
| Short term investments | 226.50M | 0.00M |
| Accounts payable | 7.99M | 3.86M |
| Accumulated other comprehensive income | 0.06M | - |
| Non currrent assets other | 4.13M | 2.08M |
| Non current assets total | 45.59M | 13.21M |
| Capital lease obligations | 13.83M | 9.54M |
| Breakdown | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 |
| Investments | -226.44M | 0.00M |
| Total cashflows from investing activities | -237.04M | - |
| Net borrowings | 0.00M | 0.60M |
| Total cash from financing activities | 447.81M | 105.01M |
| Net income | -191.94M | -88.66M |
| Change in cash | 59.71M | 49.77M |
| Begin period cash flow | 49.81M | 0.05M |
| End period cash flow | 109.53M | 49.81M |
| Total cash from operating activities | -151.06M | -18.82M |
| Issuance of capital stock | 453.61M | 102.04M |
| Depreciation | 5.85M | 0.35M |
| Other cashflows from investing activities | -1.56M | - |
| Other cashflows from financing activities | 447.25M | - |
| Capital expenditures | 6.64M | 36.42M |
| Change in working capital | 6.43M | 4.85M |
| Stock based compensation | 15.85M | 5.95M |
| Other non cash items | 17.27M | 58.68M |
| Free cash flow | -157.70M | -55.24M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| KARD Kardigan, Inc. Common Stock |
-0.18 1.26% |
14.13 | - | - | - | 2.90 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 |
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.
506 Carnegie Center Drive, Princeton, NJ, United States, 08540
(415) 573-3220
241
| Name | Title | Year Born |
|---|---|---|
| Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA | Co-Founder, President, CEO & Chairman | 1973 |
| Dr. Jay Edelberg M.D., Ph.D. | Co-founder & Chief Medical Officer | 1964 |
| Ms. Brianne Puglisi | Chief Financial Officer | 1987 |
| Dr. Bob McDowell Ph.D. | Co-founder & Scientific Advisor | NA |
| Dr. Leslie A. Leinwand Ph.D. | Co-Founder | NA |
| Dr. Elizabeth McNally M.D., Ph.D. | Co-Founder | 1961 |
| Mr. Donald Mackenzie Ph.D. | Chief Technical Operations Officer | NA |
| Mr. Clayton Robertson | Vice President of Investor Relations | NA |
| Mr. John B. Moriarty Jr., ESQ., J.D. | Chief Legal Officer & Corporate Secretary | 1968 |
| Ms. Emily Faucette | Chief Communications Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...